Company Analysis Repare Therapeutics Inc.
1. Summary
Advantages
- Price (3.58 $) is less than fair price (4.65 $)
- The stock's return over the last year (-26.34%) is higher than the sector average (-49.7%).
Disadvantages
- Dividends (0%) are below the sector average (0.5496%).
- Current debt level 1.34% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-44.23%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Repare Therapeutics Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 8.2% | 2.5% | 0.6% |
| 90 days | -9.1% | -35.8% | 8.4% |
| 1 year | -26.3% | -49.7% | 33.9% |
RPTX vs Sector: Repare Therapeutics Inc. has outperformed the "Healthcare" sector by 23.36% over the past year.
RPTX vs Market: Repare Therapeutics Inc. has significantly underperformed the market by -60.24% over the past year.
Stable price: RPTX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: RPTX with weekly volatility of -0.5065% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (3.58 $) is lower than the fair price (4.65 $).
Price significantly below the fair price: The current price (3.58 $) is 29.9% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (7.42) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (7.42) is lower than that of the market as a whole (48.12).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.46) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (1.46) is lower than that of the market as a whole (3.1).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (6.04) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (6.04) is lower than that of the market as a whole (10.15).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.78) is higher than that of the sector as a whole (-22.12).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.78) is lower than that of the market as a whole (18.05).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 49.48% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (49.48%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-44.23%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-44.23%) is lower than that of the market as a whole (10.88%).
5.5. ROA
ROA vs Sector: The company's ROA (-36.94%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-36.94%) is lower than that of the market as a whole (6.5%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-44.89%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-44.89%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5496%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 01.04.2024 | Koehler Maria EVP, CHIEF MEDICAL OFFICER |
Sale | 4.66 | 1 398 | 300 |
| 01.04.2024 | Zinda Michael EVP, CHIEF SCIENTIFIC OFFICER |
Sale | 4.66 | 1 911 | 410 |
| 01.04.2024 | Forte Steve EVP, CHIEF FINANCIAL OFFICER |
Sale | 4.61 | 3 637 | 789 |
| 01.04.2024 | Segal Lloyd Mitchell PRESIDENT AND CEO |
Sale | 4.63 | 11 533 | 2 491 |
| 28.03.2024 | Koehler Maria EVP, CHIEF MEDICAL OFFICER |
Sale | 4.64 | 2 320 | 500 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
